Boehringer Ingelheim has announced that the company's biopharmaceutical contract manufacturing business and Molecular Partners, a biotech company, have entered into a strategic manufacturing collaboration.
Under the terms of the agreement, Boehringer Ingelheim will be responsible for the generation of E. coli production strains and the manufacture of tox and clinical stage material for multiple DARPin products supplying Molecular Partners' DARPin pipeline.
DARPins are a new generation of target-binding proteins which can be isolated from large libraries. The DARPin platform is an efficient product generating engine creating differentiated and high quality drugs at unmatched speed. Each drug candidate profits from a wide range of beneficial biophysical properties, including high stability and solubility, high yield and low-cost microbial production.
Simon Sturge, corporate senior vice president Boehringer Ingelheim Biopharmaceuticals commented: "We are happy to have entered into this collaboration with Molecular Partners as we believe the DARPin platform will play an important role in the development of next generation antibody like proteins. This agreement reflects the strategy of Boehringer Ingelheim and its new brand Boehringer Ingelheim BioXcellence to be dedicated and committed to the development of highly innovative molecule platforms and projects."
Christian Zahnd, CEO of Molecular Partners said: "Boehringer Ingelheim Biopharmaceuticals is the ideal partner to support us with highest quality GMP production capacity. This collaboration is a further commitment that Molecular Partners establishes a strong proprietary DARPin pipeline and it will allow us to develop DARPin based products for patients in need at highest quality and speed."